Skip to main content

Table 3 Primary endpoint-related events in the overall population and in patients aged 75 years and older. Reported as N (%) unless otherwise indicated

From: EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Event Arm A, 100 mg/m2 Arm B, 125 mg/m2
All (N = 79) Pts aged 75+ (N = 33) All (N = 79) Pts aged 75+ (N = 33)
Investigator reported
 Pts with reported event 69 (87) 31 (94) 71 (90) 29 (88)
 PD 61 (77) 28 (85) 60 (76) 23 (70)
 FD 4 (5) 1 (3) 7 (9) 5 (13)
 Death 4 (5) 2 (6) 4 (5) 1 (3)
Central review
 Pts with reported event 72 (91) 32 (97) 74 (94) 30 (91)
 PD 56 (71) 25 (76) 55 (70) 23 (70)
 FD 13 (16) 6 (18) 14 (18) 5 (15)
 Death 3 (4) 1 (3) 5 (6) 2 (6)
  1. FD functional decline, PD disease progression, Pts patients